# EDGAR Filing Document

**Accession Number:** 0001905495
**File Stem:** 0001493152-23-003264
**Filing Date:** 2023-2
**Character Count:** 2690
**Document Hash:** 5344bae10a52a57de51aa382d4f749d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-003264.hdr.sgml**: 20230628

**ACCESSION NUMBER**: 0001493152-23-003264

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CancerVAX, Inc.
- **CENTRAL INDEX KEY:** 0001905495
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862876870
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 351 PASEO NUEVO, FLOOR 2
- **CITY:** SANTA BARBARA
- **STATE:** CA
- **ZIP:** 93101
- **BUSINESS PHONE:** (804) 356-1810

**MAIL ADDRESS:**
- **STREET 1:** 351 PASEO NUEVO, FLOOR 2
- **CITY:** SANTA BARBARA
- **STATE:** CA
- **ZIP:** 93101

![](logo_001.jpg)

February 1, 2023

United States Securities and Exchange Commission

Attn: Arzhang Navai and Laura Crotty

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| Re: | **CancerVax, Inc.** |
|  | **Offering Statement on Form 1-A** |
|  | **Filed January 12, 2023** |
|  | **File No. 024-12130** |

---

Ladies and Gentlemen:

CancerVax, Inc (the "CancerVax" or the "Company") provides the following response (the "Response Letter") to the comments contained in the letter (the "Comment Letter") of the staff of the Division of Corporation Finance (the "Staff") of the U.S. Securities and Exchange Commission (the "Commission") dated January 19, 2023, relating to the above-referenced filing.

In response to the following enumerated comments in the Comment Letter, we respectfully submit the following responses:

<u>Part I</u>

<u>Item 3. Application of Rule 262, page i</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In Item 3 of Part I, we note that you have checked the box that "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement; however, we could not locate such disclosure. Please provide the appropriate disclosure in Part II or correct the check box in Part I.

Response:

Thank you for bringing this to our attention. We have updated Part I, Item 3 to remove the check mark for the "bad actor" disclosure as there are no bad actors involved in the Company and no such disclosure is required. We have refiled Part II as well with updated dates only.

Thank you for your assistance and review. Please contact our legal counsel, Callie Jones, at 801-303-5721 with further comments or questions.

Sincerely,

---

| | |
|:---|:---|
| **CancerVax, Inc.** |  |
| */s/ Ryan Davies* | |
| Ryan Davies |  |
| CEO and Director |  |

---